Premium
Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Author(s) -
Hamlett Eric D.,
Goetzl Edward J.,
Ledreux Aurélie,
Vasilevko Vitaly,
Boger Heather A.,
LaRosa Angela,
Clark David,
Carroll Steven L.,
CarmonaIragui María,
Fortea Juan,
Mufson Elliott J.,
Sabbagh Marwan,
Mohammed Abdul H.,
Hartley Dean,
Doran Eric,
Lott Ira T.,
Granholm AnnCharlotte
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.08.012
Subject(s) - neuropathology , microvesicles , dementia , tau protein , exosome , down syndrome , disease , alzheimer's disease , biomarker , medicine , neuroscience , oncology , psychology , biology , psychiatry , microrna , genetics , gene
Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non‐AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid β (Aβ) peptides and phosphorylated‐tau in neuronal exosomes may document preclinical AD. Methods AD neuropathogenic proteins Aβ 1–42 , P‐T181‐tau, and P‐S396‐tau were quantified by enzyme‐linked immunosorbent assays in extracts of neuronal exosomes purified from blood of individuals with DS and age‐matched controls. Results Neuronal exosome levels of Aβ 1–42 , P‐T181‐tau, and P‐S396‐tau were significantly elevated in individuals with DS compared with age‐matched controls at all ages beginning in childhood. No significant gender differences were observed. Discussion These early increases in Aβ 1–42 , P‐T181‐tau, and P‐S396‐tau in individuals with DS may provide a basis for early intervention as targeted treatments become available.